The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Open accessAbstract
Neurotoxic amyloid beta peptide (Abeta) accumulates in the brains of individuals with Alzheimer disease (AD). The APOE4 allele is a major risk factor for sporadic AD and has been associated with increased brain parenchymal and vascular amyloid burden. How apoE isoforms influence Abeta accumulation in the brain has, however, remained unclear. Here, we have shown that apoE disrupts Abeta clearance across the mouse blood-brain barrier (BBB) in an isoform-specific manner (specifically, apoE4 had a greater disruptive effect than either apoE3 or apoE2). Abeta binding to apoE4 redirected the rapid clearance of free Abeta40/42 from the LDL receptor-related protein 1 (LRP1) to the VLDL receptor (VLDLR), which internalized apoE4 and Abeta-apoE4 complexes at the BBB more slowly than LRP1. In contrast, apoE2 and apoE3 as well as Abeta-apoE2 and Abeta-apoE3 complexes were cleared at the BBB via both VLDLR and LRP1 at a substantially faster rate than Abeta-apoE4 complexes. Astrocyte-secreted lipo-apoE2, lipo-apoE3, and lipo-apoE4 as well as their complexes with Abeta were cleared at the BBB by mechanisms similar to those of their respective lipid-poor isoforms but at 2- to 3-fold slower rates. Thus, apoE isoforms differentially regulate Abeta clearance from the brain, and this might contribute to the effects of APOE genotype on the disease process in both individuals with AD and animal models of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using homozygous human APOE knock-in mice, previous work demonstrated that APOE4 promotes A β aggregation and impairs its clearance relative to APOE3 34,38,39 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE exerts toxic effects on the cerebrovascular system (694) and neurons (383, 384) and influences A 𝛃 clearance (60, 64, 98, 135, 256, 266, 278, 294, 315, 693), amyloid deposition (39, 256, 258, 266, 278, 314, 518, 612), and tau-related neurodegeneration (533) in an allele-dependent manner APOE4 > APOE3 > APOE2 .”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact increased rate of soluble Aβ clearance across the BBB has been experimentally confirmed in the setting of the APOE ε2 allele [32, 48].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, the contribution of ISF bulk flow to total Aβ clearance was minimal (Fig. 1B), consistent with previous studies (14, 15, 20).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When injecting low nM [ 125 I] Aβ 1-42 concentrations in mice, we found no significant amount of radioactivity in the CSF, showing that the small amounts of injected Aβ are rapidly cleared via the BBB and that a minor amount of injected Aβ is cleared via bulk flow as also observed by previous studies (8,11,12).”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, with an endocytosis rate up to 16 times faster than that of other Aβ receptors, such as VDLDR or LDLR (12,35), LRP1 may outperform other receptors in Aβ clearance, especially at higher concentrations.”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, with an endocytosis rate up to 16 times faster than that of other Aβ receptors, such as VDLDR or LDLR (12,35), LRP1 may outperform other receptors in Aβ clearance, especially at higher concentrations.”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LRP1 also binds APOE2 and APOE3 as well as APOE2-A 𝛃 and APOE3-A 𝛃 complexes at the abluminal side of the BBB, mediating their efflux from brain-toblood (135).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
The cited source says what the claim attributes to it.
In the citing paper
“Studies in animal models support that APOE4 compared with APOE3 and APOE2 diminishes A 𝛃 clearance across the BBB (58, 135), which has been confirmed in transgenic APOE4 mice (98).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
The cited source says what the claim attributes to it.
In the citing paper
“and in animal models, APOE4 compared with APOE3 and APOE2 leads to impaired clearance of A 𝛃 across the BBB (58, 98, 135) and an early BBB breakdown and transporters' dysregulation (9, 60, 85, 437).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
The cited source says what the claim attributes to it.
In the citing paper
“A recent study wherein apoE/Aβ complexes were microinjected into wildtype mouse brain revealed that Aβ bound to apoE4 is cleared more slowly than when Aβ is complexed to apoE3 or apoE2 (56).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies demonstrated that apoE isoforms can differentially affect Aβ clearance (Deane et al., 2008; Jiang et al., 2008; Castellano et al., 2011).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, recent studies strongly suggest that apoE regulates both extracellular and intracellular Aβ clearance in the brain (Bell et al., 2007; Deane et al., 2008; DeMattos et al., 2004; Jiang et al., 2008).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, apoE has been shown to regulate Aβ clearance in the brain (Bell et al., 2007; Deane et al., 2008; DeMattos et al., 2004; Jiang et al., 2008).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Aβ complexed to apoE2 and apoE3 is cleared out of the brain at a significantly faster rate than Aβ complexed to apoE4 (Deane et al., 2008).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“A recent study has shown that the brain to blood clearance of lipidated apoE4 in the mouse brain is significantly lower than the clearance of apoE3 and apoE2 (Deane et al., 2008).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Accumulating recent evidence strongly suggests that when human apoE is complexed with Aβ, the brain to blood clearance of Aβ is actually decreased compared to that of free Aβ (Bell et al., 2007; Deane et al., 2008; Ito et al., 2007).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“In animal models, Aβ–ApoE2 and Aβ–ApoE3 complexes are cleared by the blood brain barrier (BBB) at a substantially higher rate than Aβ–ApoE4 complexes [23].”
From The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? (2019) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“These results suggest the LDLR overexpression in neurons and astrocytes (18) likely increases BBB-mediated Aβ clearance through an indirect mechanism involving other apoE receptors at the BBB, such as LRP1—a receptor shown to directly mediate Aβ clearance across the BBB (14, 15, 26).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“our work strongly suggests that LDLR influences Aβ metabolism by affecting its clearance from the brain into blood, a mechanism previously suggested only for LRP1 and VLDLR (13–15, 26).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Although low-density lipoprotein receptor-related protein 1 (LRP1) has been well characterized for its role in BBB-mediated Aβ clearance (13–15), whether LDLR plays a role in Aβ clearance across the BBB is unclear.”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“ApoE has been shown to impede the clearance of Aβ from brain ISF (13, 15, 43); therefore, it is likely that the reduction of apoE levels with LDLR overexpression facilitates greater ISF Aβ clearance across the BBB.”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies suggest that transport across the BBB is a major elimination route for brain Aβ (8,11,12,15).”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, levels of apoE in human cerebrospinal fluid do display genotype-dependent pattern similar to the pattern in plasma, further murine interstitial fluid was observed to have genotype-dependent apoE levels similar to the pattern in cerebrospinal fluid [105,112,113].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [113]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, levels of apoE in human cerebrospinal fluid do display genotype-dependent pattern similar to the pattern in plasma, further murine interstitial fluid was observed to have genotype-dependent apoE levels similar to the pattern in cerebrospinal fluid [105,112,113].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [113]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 1×
“Clearance of Alzheimer’s amyloid β(1-40)-peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
BackgroundA68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1×
“Clearance of Alzheimer’s amyloid β(1-40)-peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
BackgroundShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Self-citationRovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284
Flagged first, then by citations
1 of the 71 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Tanzi, 2004, Neuron., 43, 605
- 10.1042/0264-6021:3480359 · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 767
Capillary CAA and perivascular Aβ-deposition: Two distinct features of Alzheimer's disease pathology
Attems, J., Yamaguchi, H., Saido, T. C., & Thal, D. R. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.030 · Cited by 63
Transcriptional Effects of ApoE4: Relevance to Alzheimer’s Disease
Theendakara, V., Peters-Libeu, C. A., Bredesen, D. E., & Rao, R. V. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0757-2 · Cited by 63
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
Clusterin in Alzheimer's disease
Wu, Z., Yu, J., Li, Y., & Tan, L. (2012) · Advances in clinical chemistry · doi:10.1016/b978-0-12-394317-0.00011-x · Cited by 63
Poustforoosh, A., Nematollahi, M. H., Hashemipour, H., & Pardakhty, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.015 · Cited by 62
Naughton, B. J., Duncan, F. J., Murrey, D. A., Meadows, A. S., Newsom, D. E., Stoicea, N., White, P., Scharre, D. W., McCarty, D. M., & Fu, H. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140606 · Cited by 61
Tang, J. X., Eckenhoff, M. F., & Eckenhoff, R. G. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181b80939 · Cited by 60
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60
Zou, C., Mifflin, L., Hu, Z., Zhang, T., Shan, B., Wang, H., Xing, X., Zhu, H., Adiconis, X., Levin, J. Z., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108447 · Cited by 61
A New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model
Rudge, J. D. (2022) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210299 · Cited by 58
Spectroscopic Signature for Stable β-Amyloid Fibrils versus β-Sheet-Rich Oligomers
Lomont, J. P., Rich, K. L., Maj, M., Ho, J.-J., Ostrander, J. S., & Zanni, M. T. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b10765 · Cited by 58
Arold, S. P., Sullivan, P. M., Bilousova, T. V., Teng, E., Miller, C. A., Poon, W. W., Vinters, H. V., Cornwell, L. B., Saing, T., Cole, G. M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0892-1 · Cited by 58
Giménez‐Llort, L., Rivera-Hernández, G., Marin‐Argany, M., Sánchez‐Quesada, J. L., & Villegas, S. (2013) · mAbs · doi:10.4161/mabs.25424 · Cited by 60
RETRACTED: Gene regulation by antisense transcription: A focus on neurological and cancer diseases
Najafi, S., Tan, S. C., Raee, P., Rahmati, Y., Asemani, Y., Lee, E. H. C., Hushmandi, K., Zarrabi, A., Aref, A. R., Ashrafizadeh, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112265 · Cited by 56
RetractedRaha‐Chowdhury, R., Henderson, J. W., Raha, A. A., Vuono, R., Bickerton, A., Jones, E. A., Fincham, R., Allinson, K. S. J., Holland, A. J., & Zaman, S. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181179 · Cited by 57
Esiri, M. M., Chance, S. A., Joachim, C. L., Warden, D. R., Smallwood, A., Sloan, C., Christie, S., Wilcock, G. K., & Smith, A. D. (2014) · Brain Pathology · doi:10.1111/bpa.12221 · Cited by 56
Prenatal high‐fat diet alters the cerebrovasculature and clearance of β‐amyloid in adult offspring
Hawkes, C. A., Gentleman, S., Nicoll, J. A. R., & Carare, R. O. (2014) · The Journal of Pathology · doi:10.1002/path.4468 · Cited by 56
Open Innovation for Phenotypic Drug Discovery: The PD2 Assay Panel
Lee, J. A., Chu, S., Willard, F. S., Cox, K. L., Galvin, R. J. S., Peery, R. B., Oliver, S. E., Oler, J., Meredith, T. D., Heidler, S. A., et al. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111405379 · Cited by 59
Dong, H. K., Gim, J., Yeo, S. H., & Kim, H. (2016) · Gene · doi:10.1016/j.gene.2016.10.022 · Cited by 57
Preventing P-gp Ubiquitination Lowers Aβ Brain Levels in an Alzheimer’s Disease Mouse Model
Hartz, A. M. S., Zhong, Y., Shen, A. N., Abner, E. L., & Bauer, B. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00186 · Cited by 54
Bilousova, T. V., Melnik, M., Miyoshi, E., Gonzalez, B. L., Poon, W. W., Vinters, H. V., Miller, C. A., Corrada, M. M., Kawas, C. H., Hatami, A., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.04.010 · Cited by 57
Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Uddin, M. S., Hasana, S., Hossain, M. F., Islam, M. S., Behl, T., Perveen, A., Hafeez, A., & Ashraf, G. M. (2020) · Current Gene Therapy · doi:10.2174/1566523220666201123112822 · Cited by 53
Association between the ABCG2 C421A polymorphism and Alzheimer's disease
Fehér, Á., Juhász, A., László, A., Pákáski, M., Kálmán, J., & Janka, Z. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.06.044 · Cited by 52
Association Between ApoE Phenotypes and Telomere Erosion in Alzheimer’s Disease
Takata, Y., Kikukawa, M., Hanyu, H., Koyama, S., Shimizu, S., Umahara, T., Sakurai, H., Iwamoto, T., Ohyashiki, K., & Ohyashiki, J. H. (2011) · The Journals of Gerontology Series A · doi:10.1093/gerona/glr185 · Cited by 52
Initiative, A. D. N., Liu, Y., Tan, L., Wang, H.-F., Liu, Y., Hao, X., Tan, C., Jiang, T., Liu, B., Zhang, D., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9388-7 · Cited by 53
The case for blood–brain barrier dysfunction in the pathogenesis of Alzheimer's disease
Jeynes, B., & Provias, J. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22527 · Cited by 51
Salameh, T. S., Rhea, E. M., Banks, W. A., & Hanson, A. J. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216660770 · Cited by 51
Akram, A., Schmeidler, J., Katsel, P., Hof, P. R., & Haroutunian, V. (2010) · Brain Research · doi:10.1016/j.brainres.2010.01.006 · Cited by 50
Cholesterol and Alzheimer's disease: A still poorly understood correlation
Ricciarelli, R., Canepa, E., Marengo, B., Marinari, U. M., Poli, G., Pronzato, M. A., & Domenicotti, C. (2012) · IUBMB Life · doi:10.1002/iub.1091 · Cited by 50
Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing
Bachmeier, C. J., Shackleton, B., Ojo, J. O., Paris, D., MULLAN, M. J., & Crawford, F. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8318-6 · Cited by 50
Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias
Yassine, H. N., Self, W. K., Kerman, B. E., Santoni, G., Shanmugam, N. K. N., Abdullah, L. I., Golden, L. R., Fonteh, A. N., Harrington, M. G., Gräff, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12845 · Cited by 52
In Vivo and In Vitro Effects of an Apolipoprotein E Mimetic Peptide on Amyloid-β Pathology
Handattu, S. P., Monroe, C. E., Nayyar, G., Palgunachari, M. N., Kadish, I., van Groen, T., Anantharamaiah, G. M., & Garber, D. W. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122377 · Cited by 50
Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
Kline, A. D. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt135 · Cited by 53
Schreiber, S., Wilisch-Neumann, A., Schreiber, F., Assmann, A., Scheumann, V., Perosa, V., Jandke, S., Mawrin, C., Carare, R. O., & Werring, D. J. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12576 · Cited by 50
A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier
Bachmeier, C. J., Paris, D., Beaulieu‐Abdelahad, D., Mouzon, B., MULLAN, M. J., & Crawford, F. (2012) · Neurodegenerative Diseases · doi:10.1159/000337231 · Cited by 53
The potential applications of Apolipoprotein E in personalized medicine
Villeneuve, S., Brisson, D., Marchant, N. L., & Gaudet, D. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00154 · Cited by 50
Walia, V., Kaushik, D., Mittal, V., Kumar, K., Verma, R., Parashar, J., Akter, R., Rahman, M. H., Bhatia, S., Al-Harrasi, A., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02617-1 · Cited by 47
Dysfunction of the Blood-brain Barrier in Cerebral Microbleeds: from Bedside to Bench
Wang, H., Zhang, C., Qiu, Y., Chen, A., Li, Y., & Hu, B. (2021) · Aging and Disease · doi:10.14336/ad.2021.0514 · Cited by 47
Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease
Campos‐Peña, V., Pichardo-Rojas, P. S., Sánchez-Barbosa, T., Ortíz-Islas, E., Rodríguez-Pérez, C. E., Montes, P., Ramos-Palacios, G., Silva‐Adaya, D., Quintana, R. V., Cerna-Cortés, J. F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012092 · Cited by 47
Emerging Roles of Meningeal Lymphatic Vessels in Alzheimer’s Disease
Guo, X., Zhang, G., Peng, Q., Huang, L., Zhang, Z., & Zhang, Z. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221016 · Cited by 49
ApoE and cerebral insulin: Trafficking, receptors, and resistance
Rhea, E. M., Raber, J., & Banks, W. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104755 · Cited by 50
Alzheimer's disease: brain expression of a metabolic disorder?
Merlo, S., Spampinato, S. F., Canonico, P. L., Copani, A., & Sortino, M. A. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.05.005 · Cited by 50
Raulin, A.-C., Kraft, L., Al-Hilaly, Y. K., Xue, W.-F., McGeehan, J. E., Atack, J. R., & Serpell, L. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.019 · Cited by 47
Matsumoto, K., Chiba, Y., Fujihara, R., Kubo, H., Sakamoto, H., & Ueno, M. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1366-7 · Cited by 46
Alzheimer's Disease: Another Target for Heparin Therapy
Bergamaschini, L. C., Rossi, E., Vergani, C., & Simoni, M. G. D. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.100 · Cited by 46
Wu, Z., Yang, B., Liu, C., Liang, G., Liu, W., Pickup, S., Meng, Q., Tian, Y., Li, S., Eckenhoff, M. F., et al. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000075 · Cited by 46
Patel, P., & Shah, J. (2017) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.06.007 · Cited by 46
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease
Martiskainen, H., Haapasalo, A., Kurkinen, K. M. A., Pihlajamäki, J., Soininen, H. S., & Hiltunen, M. O. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.789862 · Cited by 49
Genetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms
Takatori, S., Wang, W., Iguchi, A., & Tomita, T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_5 · Cited by 44
LilrB3 is a putative cell surface receptor of APOE4
Zhou, J., Wang, Y., Huang, G., Yang, M., Zhu, Y., Jin, C., Jing, D., Ji, K., & Shi, Y. (2023) · Cell Research · doi:10.1038/s41422-022-00759-y · Cited by 44
The Role of Reelin Signaling in Alzheimer’s Disease
Yu, N., Tan, M., Yu, J., Xie, A., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9459-9 · Cited by 47
Kim, Y. J., Seo, S. W., Park, S. B., Yang, J., Lee, J. S., Lee, J., Jang, Y. K., Kim, S. T., Lee, K. H., Lee, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02046-y · Cited by 44
Advanced Human BBB‐on‐a‐Chip: A New Platform for Alzheimer's Disease Studies
Yoon, J., Kim, J., Shah, Z., Awasthi, A., Mahajan, A., & Kim, Y. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002285 · Cited by 45
Taxifolin: A Potential Therapeutic Agent for Cerebral Amyloid Angiopathy
Saitô, S., Tanaka, M., Satoh‐Asahara, N., Carare, R. O., & Ihara, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.643357 · Cited by 45
Helmond, Z. V., Miners, J. S., Kehoe, P. G., & Love, S. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00321.x · Cited by 44
Poliakova, T., & Wellington, C. L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00671-y · Cited by 42
White Matter Hyperintensities are associated with Amyloid Burden in APOE4 Non-Carriers
Noh, Y., Seo, S. W., Jeon, S., Lee, J. M., Kim, J., Kim, G. H., Cho, H., Yoon, C. W., Kim, H. J., Ye, B. S., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130461 · Cited by 43
Borràs, C., Mercer, A., Sirisi, S., Alcolea, D., Escolà-Gil, J. C., Blanco-Vaca, F., & Tondo, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169356 · Cited by 39
Multi-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 43
Bachmeier, C., Beaulieu-Abdelahad, D., Crawford, F., Mullan, M., & Paris, D. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9866-6 · Cited by 39
Hunter, S., Arendt, T., & Brayne, C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8445-3 · Cited by 41
Madadi, S., Schwarzenbach, H., Saidijam, M., Mahjub, R., & Soleimani, M. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0354-3 · Cited by 41
Persson, T., Lattanzio, F., Calvo‐Garrido, J., Rimondini, R., Rubio-Rodrigo, M., Sundström, E., Maioli, S., Matton, A., & Cedazo-Mı́nguez, Á. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150738 · Cited by 44
Homocysteine, Another Risk Factor for Alzheimer Disease, Impairs Apolipoprotein E3 Function
Minagawa, H., Watanabe, A., Akatsu, H., Adachi, K., Ohtsuka, C., Terayama, Y., Hosono, T., Takahashi, S., Wakita, H., Jung, C.-G., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.146258 · Cited by 40
Sagare, A. P., Bell, R. D., Srivastava, A., Sengillo, J. D., Singh, I., Nishida, Y., Chow, N., & Zloković, B. V. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.439570 · Cited by 42
Self-citationZekonyte, J., Sakai, K., Nicoll, J. A. R., Weller, R. O., & Carare, R. O. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.08.025 · Cited by 40
Chen, Y. L., Wang, L.-Y., Chen, Y., Gao, J. Y., Marshall, C., Cai, Z., Hu, G., & Xiao, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.12.039 · Cited by 40
The Role of Apolipoprotein E Isoforms in Alzheimer’s Disease
Roda, A. R., Montoliu‐Gaya, L., & Villegas, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180740 · Cited by 41
High‐affinity multivalent interactions between apolipoprotein E and the oligomers of amyloid‐β
Ghosh, S., Sil, T. B., Dolai, S., & Garai, K. (2019) · FEBS Journal · doi:10.1111/febs.14988 · Cited by 40
Raman, S., Brookhouser, N., & Brafman, D. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104788 · Cited by 41
Gene-Environment Interaction of Body Mass Index and Apolipoprotein E ε4 Allele on Cognitive Decline
Rajan, K. B., Skarupski, K. A., Rasmussen, H. E., & Evans, D. A. (2013) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000013 · Cited by 39
Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β
Chai, A. B., Lam, H. H. J., Kockx, M., & Gelissen, I. C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158980 · Cited by 41
The vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 39
Regulation of Cerebral Cholesterol Metabolism in Alzheimer Disease
Reiss, A. B., & Voloshyna, I. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318246d973 · Cited by 38
Jurcău, A., & Simion, A. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200303121016 · Cited by 38
The role of ApoE-mediated microglial lipid metabolism in brain aging and disease
Yen, J.-H. J., & Yu, I.-C. I. (2023) · Immunometabolism · doi:10.1097/in9.0000000000000018 · Cited by 38
Can insulin signaling pathways be targeted to transport Aβ out of the brain?
Vandal, M., Bourassa, P., & Calon, F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00114 · Cited by 37
Fitz, N. F., Tapias, V., Cronican, A. A., Castranio, E. L., Saleem, M., Carter, A. Y., Lefterova, M. I., Lefterov, I. M., & Koldamova, R. P. (2015) · Brain · doi:10.1093/brain/awv293 · Cited by 38
Lipid efflux mechanisms, relation to disease and potential therapeutic aspects
Castaño, D., Rattanasopa, C., Monteiro-Cardoso, V. F., Corlianò, M., Liu, Y., Zhong, A., Rusu, M., Liehn, E. A., & Singaraja, R. R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.013 · Cited by 37
ApoE4-Mediated Blood Brain Barrier Damage in Alzheimer's Disease: Progress and Prospects
Zhou, X., Shi, Q., Zhang, X., Gu, L., Li, J., Ju, Y., Hu, M., Zhao, X., & Li, Q. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110670 · Cited by 40
Association of ApoE and LRP mRNA levels with dementia and AD neuropathology
Akram, A. M., Schmeidler, J., Katsel, P., Hof, P. R., & Haroutunian, V. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.04.010 · Cited by 37
Epilepsy: neuroinflammation, neurodegeneration, and APOE genotype
Aboud, O., Mrak, R. E., Boop, F. A., & Griffin, W. S. T. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-41 · Cited by 37
The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Daniele, A., Bellomo, A., Solfrizzi, V., et al. (2023) · Biology · doi:10.3390/biology12121529 · Cited by 39
Yang, Y. J., Cudaback, E., Jorstad, N. L., Hemingway, J. F., Hagan, C. E., Melief, E. J., Li, X., Yoo, T., Khademi, S. B., Montine, K. S., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.009 · Cited by 37
Endosomal-Lysosomal Processing of Neurodegeneration-Associated Proteins in Astrocytes
Wong, C.-O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145149 · Cited by 31
Rolyan, H., Feike, A. C., Upadhaya, A. R., Waha, A., Dooren, T. V., Haass, C., Birkenmeier, G., Pietrzik, C. U., LEUVEN, F. V., & Thal, D. R. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0572-7 · Cited by 39
Sortilin, a novel APOE receptor implicated in Alzheimer disease
Carlo, A.-S. (2013) · Prion · doi:10.4161/pri.26746 · Cited by 40
Nwabuisi‐Heath, E., Rebeck, G. W., LaDu, M. J., & Yu, C. (2013) · ASN NEURO · doi:10.1042/an20130043 · Cited by 38
Wainwright, L., Hargreaves, I. P., Georgian, A. R., Turner, C., Dalton, R. N., Abbott, N. J., Heales, S., & Preston, J. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103236 · Cited by 36
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42
The Imbalance of Vascular Molecules in Alzheimer's Disease
Bell, R. D. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121060 · Cited by 37
APOE genetic associations with seizure development after severe traumatic brain injury
Miller, M. A., Conley, Y. P., Scanlon, J. M., Ren, D., Kamboh, M. I., Niyonkuru, C., & Wagner, A. K. (2010) · Brain Injury · doi:10.3109/02699052.2010.520299 · Cited by 37
Sweet, R. A., MacDonald, M. L., Kirkwood, C. M., Ding, Y., Schempf, T. A., Jones-Laughner, J., Kofler, J., Ikonomović, M. D., López, O. L., Garver, M. E., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.056580 · Cited by 36
Pankiewicz, J. E., Baquero-Buitrago, J., Sanchez, S., Lopez-Contreras, J., Kim, J., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0156-1 · Cited by 34
“fact increased rate of soluble Aβ clearance across the BBB has been experimentally confirmed in the setting of the APOE ε2 allele [32, 48].”
BackgroundSelf-citationMolecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease
Żukowska, J., Moss, S. J., Subramanian, V., & Acharya, K. R. (2023) · FEBS Journal · doi:10.1111/febs.16939 · Cited by 36
Lipid metabolism and neuroinflammation: What is the link?
Tiwari, V., & Simons, M. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241232 · Cited by 39
Ruzali, W. A. W., Kehoe, P. G., & Love, S. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121336 · Cited by 36
Role for apolipoprotein E in neurodegeneration and mercury intoxication
Lopez, M. E. C. (2017) · Frontiers in Bioscience-Elite · doi:10.2741/e819 · Cited by 35
Aging of the Vascular System and Neural Diseases
Watanabe, C., Imaizumi, T., Kawai, H., Suda, K., Honma, Y., Ichihashi, M., Ema, M., & Mizutani, K. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.557384 · Cited by 38
Metadata
- Authors
- Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V.
- Affiliations
- University of Rochester Medicine (US)
- Washington University in St. Louis (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2008-12-01
- Volume
- 118
- Issue
- 12
- Pages
- 4002-4013
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2582453
- OpenAlex
- W2138992210
- Cited by
- 771
- References
- 71
- Citations by year
- 2026: 35 · 2025: 39 · 2024: 51 · 2023: 40 · 2022: 42 · 2021: 48 · 2020: 47 · 2019: 47 · 2018: 35 · 2017: 49 · 2016: 38 · 2015: 51 · 2014: 48 · 2013: 41 · 2012: 52
- FWCI
- 24.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- National Institutes of Health (R37 NS34467, NS34467, AG13956, R37 AG13956)
- National Institute on Aging (R37AG023084, R37AG13956, R37AG013956)
- National Institute of Neurological Disorders and Stroke (R37NS034467, R37NS34467)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- APOE isoforms, APOE ε4, Alzheimer's disease, blood-brain barrier, LRP1, VLDLR, APOE2, APOE3, amyloid accumulation
- MeSH terms
- Alzheimer Disease, Animals, Astrocytes, Blood-Brain Barrier, Disease Models, Animal, Humans, Male, Receptors, LDL, Amyloid beta-Peptides, Protein Isoforms, Tumor Suppressor Proteins, Low Density Lipoprotein Receptor-Related Protein-1, Mice, Apolipoprotein E3, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
